Opposition leader and Botany MP Christopher Luxon toured local medicinal cannabis company last week.
On May 26, Luxon visited East Tamaki-based Helius Therapeutics, where he viewed production of the first New Zealand-grown and made products, due to be launched this year.
He also took the opportunity to meet and speak with Helius staff.
“Innovative businesses like Helius will play a key role in New Zealand’s economic recovery.
“It is great to see them leading the way in research and development, as well as now delivering premium, natural New Zealand products to patients here and, soon, overseas,” Luxon says.
“Best of all, it’s coming out of the very productive electorate of Botany.
Chief executive of Helius Carmen Doran says the visit to NZ’s newest industry was “well-received”.
“During his tour, he could see we’re busy delivering for the domestic market, with exports starting later this year.”
His visit follows the Ministry of Health renewing and expanding Helius licence, allowing the company to “register additional medicines and make active ingredients onsite from raw cannabis material”.
Helius reports that locally grown products are now imminent with organic dried flower from the South Island due to arrive en masse at the company soon.
